Pfizer INC Form 4 insider transactions

Pfizer Executive Vice President Payal Sahni reported the earn-out and exercise of 56,888 stock appreciation rights, resulting in a net change in her direct common stock holdings.

Pfizer Executive Vice President Douglas M. Lankler reported the exercise of stock appreciation rights and subsequent share adjustments for tax and exercise price obligations.

Pfizer's SVP & Controller, Jennifer B. Damico, settled 17,558 stock appreciation rights, resulting in a net beneficial ownership of 12,696 common shares.

Pfizer's Chairman and CEO, Albert Bourla, reported the exercise of stock appreciation rights and subsequent share dispositions for tax and exercise price obligations.

Pfizer Executive Vice President Lidia Fonseca reported the exercise of stock appreciation rights and subsequent share disposals for tax and exercise price coverage.

Pfizer Executive Vice President Michael McDermott reported a series of equity transactions, including the earn-out of stock appreciation rights and subsequent share dispositions for tax and exercise costs.

Pfizer's President of R&D, Christoffel Boshoff, received performance share awards and had shares withheld for tax obligations.

Pfizer's President of R&D, Christoffel Boshoff, reported a disposition of 816 common shares to cover tax liabilities upon the vesting of restricted stock units.

Pfizer's SVP & Controller, Jennifer B. Damico, disposed of 419 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Pfizer's President of R&D, Christoffel Boshoff, reported a routine disposition of 12,887 shares to cover tax liabilities from restricted stock unit vesting.

Pfizer's Chairman and CEO, Albert Bourla, acquired 79 phantom stock units valued at $25.58 each, increasing his beneficial ownership to 743,136 units.

Pfizer Director Mortimer J. Buckley acquired 1,506.024 phantom stock units as deferred compensation, increasing his beneficial ownership to 15,078.063 units.

Pfizer Director Joseph Echevarria acquired 1,857.43 phantom stock units on December 31, 2025, as deferred compensation, increasing his total beneficial ownership to 149,314.146 units.

Pfizer director Shantanu Narayen acquired 2,008.032 phantom stock units as deferred compensation, settling in cash or common stock post-retirement.

Pfizer Director James Quincey reported the acquisition of 1,556.225 phantom stock units as deferred director's compensation.

Pfizer Director James C. Smith acquired 1,807.229 phantom stock units as deferred compensation, increasing his total beneficial ownership to 166,119.84 units.

Pfizer Director Cyrus Taraporevala acquired 1,506.024 phantom stock units as deferred compensation, increasing his total beneficial ownership to 25,349.741 units.

Pfizer CEO Albert Bourla acquired 24 phantom stock units under a deferred compensation plan, increasing his beneficial ownership to 743,147 units.

Pfizer Inc. Chairman and CEO Albert Bourla acquired 23 phantom stock units on December 15, 2025, through a deferred compensation plan.

Pfizer's Chairman and CEO, Albert Bourla, acquired 23 phantom stock units at $25.74 each, increasing his beneficial ownership to 743,115 units.

Pfizer Inc.'s Chairman and CEO, Albert Bourla, acquired 24 phantom stock units on November 14, 2025, increasing his beneficial ownership to 743,548 units.

Pfizer Chairman and CEO Albert Bourla acquired 24 phantom stock units through a deferred compensation plan, increasing his beneficial ownership.

Pfizer Inc. Chairman and CEO Albert Bourla acquired 25 phantom stock units as part of a deferred compensation plan.

Pfizer Chairman and CEO Albert Bourla acquired 83 phantom stock units under a deferred compensation plan, increasing his beneficial ownership to 731,058 units.

Pfizer Director Cyrus Taraporevala acquired 1,471.743 phantom stock units as deferred compensation, increasing his total beneficial ownership to 23,444.776 units.

Pfizer Director James C. Smith acquired 1,766.091 phantom stock units as deferred compensation, increasing his beneficial ownership to 161,563.412 units.

Pfizer Director James Quincey acquired 1,520.801 phantom stock units as deferred compensation, increasing his total beneficial ownership to 71,917.073 units.

Pfizer Inc. Director Shantanu Narayen acquired 1,962.323 phantom stock units as deferred compensation, increasing his beneficial ownership to 178,125.307 units.

Pfizer Director Joseph Echevarria acquired 1,815.149 phantom stock units as deferred compensation, increasing his beneficial ownership to 144,989.542 units.

Pfizer's Chairman and CEO, Albert Bourla, acquired 24 phantom stock units through a deferred compensation plan, increasing his beneficial ownership to 730,773 units.